SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
4 references·10 citing·46 second hop
Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing (2009)Efficacy Does Not Necessarily Translate t…What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)What Does the Value of Modern…The experimental consumer price index for elderly Americans (CPI-E): 1982-2007 (2008)The experimental consumer pri…The Health Utilities Index (HUI): concepts, measurement properties and applications. (2003)The Health Utilities Index (H…Development of WHO guidelines on generalized cost-effectiveness analysis (2000)Development of WHO guidelines…Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan (2018)Availability of anticancer me…Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆ (2017)Cost-effectiveness of nivolum…Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective (2016)Cost-effectiveness of adding …Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions? (2015)Why Are Cancer Drugs So Expen…Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic (2015)Patients and Physicians Can D…High Cancer Drug Prices in the United States: Reasons and Proposed Solutions (2014)High Cancer Drug Prices in th…Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care (2014)Delivering maximum clinical b…Cost effectiveness of telecare management for pain and depression in patients with cancer: results from a randomized trial (2014)Cost effectiveness of telecar…The economic pressures for biosimilar drug use in cancer medicine (2012)The economic pressures for bi…Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis (2012)Ipilimumab in 2nd line treatm…Association of Insurance with Cancer Care Utilization and Outcomes (2008)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis (2013)Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act (2018)Financial Hardship and Quality of Life among African American and White Cancer Survivors: The Role of Limiting Care Due to Cost (2019)Financial toxicity associated with treatment of localized prostate cancer (2019)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)The Price of Inequality: How Today's Divided Society Endangers Our Future (2015)Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries (2017)Trajectories of Injectable Cancer Drug Costs After Launch in the United States (2017)US Pharma's Financialized Business Model (2017)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)The NICE Cost-Effectiveness Threshold (2008)World Health Report (2013)Delivering affordable cancer care in high-income countries (2011)American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology (2012)Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways (2016)Cost-effectiveness thresholds: methods for setting and examples from around the world (2018)Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future (2018)Bulletin of the World Health Organization (1955)Cost-Effectiveness in Health and Medicine (1996)Generalized cost-effectiveness analysis for national-level priority-setting in the health sector (2003)Generalisability in economic evaluation studies in healthcare: a review and case studies (2004)Methods for the Economic Evaluation of Health Care Programmes (2005)Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)The Price of Inequality (2013)A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing (2016)Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement (2018)Quality of life and pharmacoeconomics in clinical trials (1996)South Korean Time Trade-Off Values for EQ-5D Health States: Modeling with Observed Values for 101 Health States (2009)Health outcomes in economic evaluation: the QALY and utilities (2010)Theory of games and economic behavior (2019)COVID-19 and Parent-Child Psychological Well-being (2020)Free for All? Lessons from the RAND Health Insurance Experiment (1995)Willingness to Pay for a Quality-adjusted Life Year (2000)Estimating the Economic Burden of Racial Health Inequalities in the United States (2011)A community empowerment approach to the HIV response among sex workers: effectiveness, challenges, and considerations for implementation and scale-up (2014)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)The Economic Burden of Head and Neck Cancer: A Systematic Literature Review (2014)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Catastrophic payments for health care in Asia (2007)The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countries (2007)Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis (2008)Pricing of oral generic cancer medicines in 25 European countries; findings and implications (2019)Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study (2021)
this work references cited by second hop

References

  • 2003The Health Utilities Index (HUI): concepts, measurement properties and applications.1,380 cited
  • 2000Development of WHO guidelines on generalized cost-effectiveness analysis578 cited
  • 2008What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?578 cited
  • 2008The experimental consumer price index for elderly Americans (CPI-E): 1982-200730 cited

Cited by

  • 2015Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?115 cited
  • 2014High Cancer Drug Prices in the United States: Reasons and Proposed Solutions114 cited
  • 2012The economic pressures for biosimilar drug use in cancer medicine92 cited
  • 2014Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care86 cited
  • 2015Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic78 cited
  • 2018Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan61 cited
  • 2017Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆52 cited
  • 2012Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis51 cited
  • 2016Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

51 cited
  • 2014Cost effectiveness of telecare management for pain and depression in patients with cancer: results from a randomized trial49 cited